The Weizmann Institute of Science announced a multi-year deal Monday with global pharmaceutical giant Pfizer.
The deal, which was signed through Weizmann's commercial arm, will see Pfizer installing a medicinal chemist on an annual, rotating basis at the Institute's National Drug Discovery Institute (DDI). The DDI is part of Weizmann's Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM)
“This is an exciting partnership for Pfizer,” said Mikael Dolsten, President of Pfizer Global Research. “We have interacted with the Weizmann Institute for many years and have confidence in their scientific vision and expertise. We anticipate that this arrangement could potentially result in meaningful discoveries in the coming years."
The collaboration could lead to further research and development agreements.